US Stock MarketDetailed Quotes

MYGN Myriad Genetics

Watchlist
  • 13.360
  • +0.190+1.44%
Close Dec 20 16:00 ET
  • 13.360
  • 0.0000.00%
Post 16:20 ET
1.22BMarket Cap-10.44P/E (TTM)

About Myriad Genetics Company

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Company Profile

SymbolMYGN
Company NameMyriad Genetics
Listing DateOct 6, 1995
Issue Price18.00
Founded1991
CEOMr. Paul J. Diaz
MarketNASDAQ
Employees2700
Fiscal Year Ends12-31
Address322 North 2200 West
CitySalt Lake City
ProvinceUtah
CountryUnited States of America
Zip Code84116
Phone1-801-584-3600

Company Executives

  • Name
  • Position
  • Salary
  • Paul J. Diaz
  • Director, President and Chief Executive Officer
  • 12.11M
  • Natalie Munk
  • Chief Accounting Officer
  • --
  • Dale Muzzey
  • Chief Scientific Officer
  • 2.23M
  • Scott J. Leffler
  • Chief Financial Officer
  • --
  • Shereen Solaiman
  • Chief People Officer
  • --
  • Mark Verratti
  • Chief Commercial Officer
  • 2.88M
  • Kevin Richard Haas
  • Chief Technology Officer
  • --
  • Samraat S. Raha
  • Chief Operating Officer
  • 5.02M
  • Margaret Ancona
  • Senior Vice President and Chief of Staff
  • --
  • S. Louise Phanstiel
  • Chairman of the Board
  • 563.49K
  • Paul M. Bisaro
  • Independent Director
  • 258.48K
  • Dr. Heiner Dreismann,PhD
  • Independent Director
  • 443.49K
  • Mark S. Davis
  • Independent Director
  • --
  • Daniel K. Spiegelman
  • Independent Director
  • 433.49K
  • Dr. Daniel M. Skovronsky, M.D.
  • Independent Director
  • 433.49K
  • Colleen F. Reitan
  • Independent Director
  • 443.49K
  • Dr. Lee N. Newcomer, M.D.
  • Independent Director
  • 447.99K
  • Rashmi Kumar
  • Independent Director
  • 433.49K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.